- CVS Health | Represented CVS Health in its $69 billion industry-transforming acquisition of Aetna.
- Boston Scientific | Represented Boston Scientific in its $5.1 billion acquisition of BTG plc.
- Genmab A/S | Advised Genmab A/S in connection with its $506 million initial public offering and listing of American Depositary Shares (ADSs) on the Nasdaq, the largest-ever biotech offering by a European issuer on a U.S. exchange.
- GlaxoSmithKline | Represented global pharmaceutical company GlaxoSmithKline in its $5.1 billion acquisition of oncology-focused biopharmaceutical company Tesaro.
- Golden Meditech | Represented Hong Kong-listed Golden Meditech on its $830 million sale of stake in China Cord Blood.
- Novartis | Represented Novartis on its $3.9 billion acquisition of Nasdaq-listed Advanced Accelerator Applications, which won “M&A Deal of the Year” at the IFLR Europe Awards 2019.
- Sun Pharmaceuticals | Represented Sun Pharmaceuticals, one of the largest specialty generic pharmaceutical companies, in its $4 billion acquisition of Ranbaxy Laboratories, Ltd.
- WuXi AppTec | Represented the underwriters on the $1 billion global offering and initial public offering of WuXi AppTec Co., Ltd on the Main Board of the Stock Exchange of Hong Kong Limited.